You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

third line treatment

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Colorectal Cancer Trial in Hangzhou (Fruquintinib Combined With Chemotherapy)

Not yet recruiting
  • Advanced Colorectal Cancer
  • Fruquintinib Combined With Chemotherapy
  • Hangzhou, Zhejing, China
    Zhejiang Cancer Institute & Hospital
Jun 29, 2023

Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With

Not yet recruiting
  • Third-line Treatment
  • +2 more
  • furquimatinib and sintilimab
  • (no location specified)
Mar 30, 2023

Metastatic Colorectal Cancer Trial (Cetuximab and irinotecan)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Cetuximab and irinotecan
  • (no location specified)
Jul 26, 2023

TAS-102 in Combination With Regorafenib or Fruquintinib for

Not yet recruiting
  • TAS 102
  • +3 more
  • (no location specified)
Aug 7, 2023

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line

Recruiting
  • Breast Neoplasms
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Mar 16, 2023

Mesotheliomas Pleural Trial in Amsterdam (Pembrolizumab, Lenvatinib)

Recruiting
  • Mesotheliomas Pleural
  • Amsterdam, Noord-Holland, Netherlands
    Antoni van Leeuwenhoekziekenhuis (NKI-AVL)
Jan 13, 2023

Metastatic Colorectal Cancer Trial in Wuhan (SBRT, Fruquintinib, Cadonilimab)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • SBRT, Fruquintinib, Cadonilimab
  • Wuhan, Hubei, China
    Cancer Center, Union Hospital, Tongji Medical College, Huazhong
Feb 18, 2023

Colorectal Cancer Trial in Shanghai (serplulimab, Fruquintinib)

Not yet recruiting
  • Colorectal Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jul 13, 2023

Ustekinumab and Tofacitinib as Third Line Therapy inMulticenter

Completed
  • Ulcerative Colitis
  • Milano, Italy
    Mariangela Allocca
Feb 13, 2023

Cancer of Colon Trial in Jerusalem (Cetuximab)

Terminated
  • Cancer of Colon
  • Jerusalem, Israel
    Hadassah Ein Kerem
Aug 2, 2022

Pancreatic Tumors Trial in Guangzhou (Surufatinib, TAS-102)

Not yet recruiting
  • Pancreatic Neoplasms
  • Guangzhou, Guangdong, China
    Cancer center of SunYat-sen University
Jul 28, 2022

Regorafenib, Raltitrexed, Colorectal Tumors Trial (Regorafenib, Raltitrexed)

Not yet recruiting
  • Regorafenib
  • +3 more
  • (no location specified)
Jun 24, 2022

Metastatic Colorectal Cancer Trial in Bronx, Houston (AlloStim)

Recruiting
  • Metastatic Colorectal Cancer
  • AlloStim
  • Florham Park, New Jersey
  • +1 more
Aug 30, 2022

Septic Shock Trial in Roanoke (Methylene Blue, Phenylephrine)

Recruiting
  • Septic Shock
  • Roanoke, Virginia
    Carilion Clinic
Jul 22, 2022

Colorectal Tumors Malignant Trial in Shanghai (Tislelizumab Combined With Cetuximab and Irinotecan, Third-line regimens)

Not yet recruiting
  • Colorectal Neoplasms Malignant
  • Tislelizumab Combined With Cetuximab and Irinotecan
  • Third-line regimens
  • Shanghai, Shanghai, China
    Tianshu Liu
Apr 18, 2022

Immunotherapy, Colorectal Cancer Trial in Fuzhou (Tislelizumab, bevacizumab, TAS-102)

Recruiting
  • Immunotherapy
  • Colorectal Cancer
  • Fuzhou, Fujian, China
  • +1 more
Jul 20, 2022

Advanced Colorectal Carcinoma, Liver Metastasis Colon Cancer Trial in Beijing (Fruquintinib, Hepatic Arterial Infusion

Recruiting
  • Advanced Colorectal Carcinoma
  • Liver Metastasis Colon Cancer
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jun 1, 2022

Triple-negative Breast Cancer Trial in Shanghai (chidamide, camrelizumab, carboplatin)

Not yet recruiting
  • Triple-negative Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 25, 2022

SCLC, Extensive Stage Trial in Zhengzhou (Utidelone, Placebo)

Recruiting
  • SCLC, Extensive Stage
  • Zhengzhou, Henan, China
    Henan Tumor Hospital
Mar 24, 2022

NSCLC Trial in Canada (Osimertinib First-Line, Platinum + Pemetrexed Chemotherapy Second-Line, Osimertinib Third-Line)

Recruiting
  • Non-Small Cell Lung Cancer
  • Osimertinib First-Line
  • +2 more
  • Vancouver, British Columbia, Canada
  • +9 more
Jun 21, 2022

Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma Trial in Guangzhou (Camrelizumab,

Not yet recruiting
  • Metastatic Gastric Adenocarcinoma
  • Metastatic Gastroesophageal Junction Adenocarcinoma
  • Guangzhou, Guangdong, China
    The Sixth Affiliated hosipital, Sun Yat-Sen University
Apr 16, 2022

Patients With Advanced Metastatic Colorectal Cancer Trial in Wuhan (Tislelizumab plus Fruquintinib and SBRT)

Active, not recruiting
  • Patients With Advanced Metastatic Colorectal Cancer
  • Tislelizumab plus Fruquintinib and SBRT
  • Wuhan, Hubei, China
    Huazhong University of Science and Technology
Aug 15, 2022

Colorectal Cancer Liver Metastases, Regorafenib Trial in Guangdong (Regorafenib and DIBIRI, Regorafenib)

Recruiting
  • Colorectal Cancer Liver Metastases
  • Regorafenib
  • Guangdong, Guangzhou, China
    Bo Zhang
Mar 20, 2023

Needs of 3L+ CP-CML and With T315I-mutated CML Patients

Completed
  • Chronic Myeloid Leukemia
  • 3L Therapy
  • T315I
  • Lyon, France
    Novartis Investigative Site
Nov 9, 2022

Endometrioid Endometrial Cancer Trial (Narazaciclib, Letrozole 2.5mg)

Not yet recruiting
  • Endometrioid Endometrial Cancer
  • (no location specified)
Feb 1, 2023